Paweł Radkowski

Dr. Paweł Radkowski


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
PRPaweł Radkowski
Paweł Radkowski
MDMaria Agnieszka Derkaczew
Maria Agnieszka Derkaczew
MMMichał Mazuchowski
Michał Mazuchowski
AMAnnas Moussa
Annas Moussa
KPKatarzyna Podhorodecka
Katarzyna Podhorodecka
MMMarta Majewska
Marta Majewska
Interactions between drugs are a common problem in Intensive Care Unit patients, as they mainly have a critical condition that often demands the administration of multiple drugs simultaneously. Antibiotics are among the most frequently used medications, as infectious diseases are often observed in ICU patients. In this review, the most important antibiotic–drug interactions, based on the pharmacokinetic and pharmacodynamic mechanisms, were gathered together and described. In particular, some of the most important interactions with main groups of antibacterial drugs were observed in patients simultaneously prescribed oral anticoagulants, NSAIDs, loop diuretics, and valproic acid. As a result, the activity of drugs can be increased or decreased, as dosage modification might be necessary. It should be noted that these crucial interactions can help predict and avoid negative consequences, leading to better patient recovery. Moreover, since there are other factors, such as fluid therapy or albumins, which may also modify the effectiveness of antibacterial therapy, it is important for anaesthesiologists to be aware of them.

19 June 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
PRPaweł Radkowski
Paweł Radkowski
JOJulia Katarzyna Oszytko
Julia Katarzyna Oszytko
KSKamil Sobolewski
Kamil Sobolewski
FTFlorian Trachte
Florian Trachte
DODariusz Onichimowski
Dariusz Onichimowski
MMMarta Majewska
Marta Majewska
Background: Due to the high prevalence of severe infections, antibiotics are frequently administered in anaesthesia and intensive care units. Despite their therapeutic efficacy, several antibiotics exhibit neurotoxic potential, resulting in central and peripheral neurological complications in patients. This review aims to summarise the current evidence on antibiotic-induced neurotoxicity, particularly in critical care settings. Methods: A comprehensive literature analysis was performed to assess the neurotoxic profiles, underlying mechanisms, and clinical manifestations associated with different antibiotic classes, including beta-lactams, fluoroquinolones, macrolides, aminoglycosides, and others. Results: Beta-lactam antibiotics (especially cephalosporins and carbapenems) are strongly associated with seizures, encephalopathy, and EEG abnormalities, mainly through GABAergic inhibition and mitochondrial dysfunction. Fluoroquinolones and macrolides can cause psychosis, insomnia, and neuropathy via NMDA activation and oxidative stress. Linezolid carries the risk of serotonin syndrome and optic neuropathy, while glycopeptides and aminoglycosides are primarily associated with ototoxicity. Risk factors include advanced age, renal or hepatic impairment, and high serum drug levels. Conclusions: The neurotoxic potential of antibiotics is a critical but under-recognised aspect of pharmacotherapy in intensive care. Improved awareness, pharmacovigilance, dose adjustment, and drug monitoring are crucial for mitigating adverse neurological effects.

23 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
PRPaweł Radkowski
Paweł Radkowski
Anna GogojewiczAnna Gogojewicz
Anna Gogojewicz
JCJoanna Maria Charasna
Joanna Maria Charasna
ŁPŁucja Pilaczyńska-Szcześniak
Łucja Pilaczyńska-Szcześniak
ŁGŁukasz Grabarczyk
Łukasz Grabarczyk
Sepsis remains one of the major challenges in modern intensive care, characterized by high mortality and complex metabolic and immunological disturbances. Given the limited effectiveness of current therapeutic strategies, increasing attention has been directed toward supportive interventions aimed at restoring metabolic homeostasis. Particular interest has been focused on selected vitamins that exhibit pleiotropic biological effects. Thus, we summarized the current evidence on the role of selected vitamins (C, D, B1, B9, B12) in the treatment and supportive management of sepsis, highlighting their mechanisms of action, potential clinical benefits, and limitations derived from available studies. A comprehensive analysis of the literature was performed, including clinical trials and meta-analyses evaluating the efficacy of vitamin supplementation in sepsis, with particular emphasis on combined interventions and randomized controlled trials in severe sepsis and septic shock. Vitamin D might demonstrate the greatest therapeutic potential, particularly in patients with severe sepsis and respiratory failure, with benefits associated with achieving appropriate therapeutic concentrations. Thiamine (vitamin B1) appears to provide potential advantages primarily in deficient patients, improving mitochondrial function and reducing the risk of renal failure. Evidence regarding folic acid (vitamin B9) and cobalamin (vitamin B12) remains inconclusive, as both deficiency and elevated serum levels have been linked to adverse outcomes. Vitamin C, despite its well-documented antioxidant and microcirculatory effects, has not yet shown consistent evidence of mortality reduction. In conclusion, current evidence suggests that vitamin supplementation might represent an adjunct to standard sepsis therapy, particularly within a personalized approach that considers nutritional status and metabolic phenotype. The development of standardized dosing protocols and well-designed clinical trials is essential to determine the efficacy and safety of phenotype-driven individualized approaches in sepsis management.

6 February 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PRPaweł Radkowski
Paweł Radkowski
JOJulia Katarzyna Oszytko
Julia Katarzyna Oszytko
KSKamil Sobolewski
Kamil Sobolewski
FTFlorian Trachte
Florian Trachte
MCMaja Czerwińska-Rogowska
Maja Czerwińska-Rogowska
MMMarta Majewska
Marta Majewska
The rapid global spread of antimicrobial resistance (AMR) has significantly reduced the effectiveness of many modern antibiotics, creating an urgent need for alternative therapeutic strategies. One promising approach is the revival and repurposing of older antimicrobial agents whose clinical potential was previously limited by toxicity concerns, pharmacokinetic challenges, or the availability of newer drugs. Recent advances in drug delivery, dosing optimization, and antimicrobial stewardship have renewed interest in these compounds as viable options for the treatment of multidrug-resistant infections. The aim of this review is to provide a comparative, clinically oriented analysis of selected “old” antibiotics, fosfomycin, colistin, streptomycin, and vancomycin, with emphasis on their current therapeutic roles, pharmacokinetic/pharmacodynamic (PK/PD) targets, toxicity mitigation strategies, resistance mechanisms, and evidence supporting combination therapies and alternative routes of administration. This narrative review was conducted using a structured PubMed search and manual reference screening, focusing on clinical, PK/PD, and translational studies relevant to the contemporary use of legacy antibiotics. The review summarises current evidence on the re-emerging clinical applications of these agents, each discussed in the context of historical use, mechanism of action, resistance patterns, and newly identified indications. Attention is given to novel formulations, combination strategies, and alternative routes of administration that enhance efficacy while limiting toxicity, including applications in biofilm-associated infections. Overall, strategic repurposing of older antibiotics represents a valuable complementary approach in the fight against AMR and may extend the therapeutic lifespan of existing agents in an era of limited antibiotic innovation.

28 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMalgorzata Braczkowska-Skibinska
Malgorzata Braczkowska-Skibinska
ELEwa Lepiarczyk
Ewa Lepiarczyk
LGLidia Glinka
Lidia Glinka
IPIwona Piotrowicz
Iwona Piotrowicz
PRPaweł Radkowski
Paweł Radkowski
MMMarta Majewska
Marta Majewska
Background/Objectives: Pupillometry offers a non-invasive method for assessing nociceptive responses during anesthesia. This study aimed to evaluate the effects of intravenous lidocaine on pupillary reflex dilation (PDR) and the Pupillary Pain Index (PPI) during general anesthesia with orotracheal intubation. Methods: In this prospective, randomized, single-blind trial, 90 ASA I–II patients aged 18–65 years, scheduled for elective surgery under general anesthesia, were enrolled. Participants were randomized into three groups: control, study (lidocaine 1.5 mg/kg), and placebo. Standardized anesthesia induction was performed using propofol, fentanyl, and rocuronium. Pupil diameter was measured using the Algiscan pupillometer. PDR was assessed during intubation, while PPI was measured five minutes post-intubation through controlled electrical stimulation. Hemodynamic parameters and BIS values were recorded throughout. Eighty-six patients completed the study. No significant differences in demographics, anesthetic drug doses, or hemodynamic parameters were noted between groups. Results: PDR during intubation showed no significant difference between the control and study groups (median dilation: 0.34 mm vs. 0.33 mm; p = 0.76), but was significantly lower in the lidocaine group compared to placebo (median dilation: 0.33 mm vs. 0.50 mm; p = 0.02). PPI scores did not differ significantly between groups (p > 0.05). A positive correlation was observed between PDR and BIS values, indicating that lighter anesthesia depth increased PDR response. No such correlation was found with PPI. Conclusions: Intravenous lidocaine attenuates the pupillary response to nociceptive stimuli during orotracheal intubation but does not influence PPI scores. Pupillometry remains a valuable adjunct for intraoperative nociceptive monitoring.

2 September 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
ŁGŁukasz Grabarczyk
Łukasz Grabarczyk
JOJulia Katarzyna Oszytko
Julia Katarzyna Oszytko
MDMaria Derkaczew
Maria Derkaczew
KSKamil Sobolewski
Kamil Sobolewski
PRPaweł Radkowski
Paweł Radkowski
Background/Objectives: Antibiotics are widely used in clinical practice, yet their potential effects on endocrine homeostasis remain insufficiently recognized. This review summarizes endocrine adverse effects associated with selected antibacterial agents, their proposed mechanisms, and clinical relevance. Methods: A narrative literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science from database inception to 10 August 2026. Clinical, pharmacovigilance, case-based, animal, in vitro, and ex vivo studies were considered. Results: Reported disturbances include SIADH-related hyponatremia, hypoglycemia, altered thyroid hormone metabolism, changes in hypothalamic–pituitary–adrenal axis activity, aldosterone dysregulation, and reproductive hormone disturbances. Selected cephalosporins and carbapenems have been associated with changes in prolactin secretion, thyroid-related parameters, and gonadal function. Fluoroquinolones have been associated with dysglycemia, while effects on reproductive hormone pathways have been reported predominantly in experimental models. Selected macrolides may influence glucocorticoid metabolism and KCNJ5-dependent aldosterone production. Linezolid has been linked to hyponatremia and hypoglycemia, while metronidazole may affect pituitary hormone secretion. Trimethoprim–sulfamethoxazole may contribute to hyponatremia, hyperkalemia, hypoglycemia, and thyroid dysfunction. The supporting evidence is heterogeneous and ranges from case reports and pharmacovigilance analyses to experimental studies. Human clinical evidence is strongest for selected disturbances of glucose and electrolyte homeostasis, whereas many reported reproductive, pituitary, thyroid, and adrenal effects remain supported predominantly by experimental or case-based evidence. Conclusions: Many proposed mechanisms remain incompletely established and cannot be directly extrapolated to routine practice. Awareness of these complications may support earlier recognition, targeted biochemical monitoring, and safer antibiotic therapy, particularly in older, critically ill, or renally impaired patients and those exposed to polypharmacy.